The global hospital acquired infection (HAI) control market is estimated at USD 25.3B in 2025 and is projected to reach USD 41.6B by 2033 (Claritas model), driven by escalating antimicrobial resistance (AMR) burden documented across 152,945 indexed academic works since 2023 (openalex:topic-volume). The single most cons The HAI control market encompasses pharmaceuticals, disinfectants, sterilization equipment, personal protective equipment, and surveillance informatics deployed to interrupt pathogen transmission within healthcare settings.
Market Size (2025)
USD 25.3 Billion
Projected (2026–2033)
USD 41.6 Billion
CAGR
6.4%
Published
May 2026
Select User License
Selected
PDF Report
USD 4,900
USD 3,200
The Hospital Acquired Infection Control Market is valued at USD 25.3 Billion and is projected to grow at a CAGR of 6.4% during 2026–2033. North America holds the largest regional share, while Asia Pacific is the fastest-growing market.
Study Period
2019–2033
Market Size (2025)
USD 25.3 Billion
CAGR (2026–2033)
6.4%
Largest Market
North America
Fastest Growing
Asia Pacific
Market Concentration
Medium
*Disclaimer: Major Players sorted in no particular order
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Global Hospital Acquired Infection Control market valued at USD 25.3 Billion in 2025, projected to reach USD 41.6 Billion by 2033 at 6.4% CAGR
Key growth driver: Escalating AMR Burden Expanding Formulary Requirements (High, +9% CAGR impact)
North America holds the largest market share, while Asia Pacific is the fastest-growing region
AI Impact: AI-driven de novo peptide sequence design is the most directly applicable AI application in the HAI anti-infective pipeline. Generative chemistry platforms — applying transformer-architecture models trained on antimicrobial peptide structural databases — can explore analogue libraries that optimize membrane-disruption potency against AMR-phenotype gram-negative organisms while minimizing host-cell toxicity.
15 leading companies profiled including 3M Company, Ecolab Inc., Cardinal Health, Inc. and 12 more
AI-driven de novo peptide sequence design is the most directly applicable AI application in the HAI anti-infective pipeline. Generative chemistry platforms — applying transformer-architecture models trained on antimicrobial peptide structural databases — can explore analogue libraries that optimize membrane-disruption potency against AMR-phenotype gram-negative organisms while minimizing host-cell toxicity. This is particularly relevant for the peptide synthesis manufacturing segment (SPPS and solution-phase convergent coupling), where lead optimization cycles that previously required 18–24 months of medicinal chemistry iteration can be compressed to 4–6 months using generative chemistry for analog optimization of stability, half-life, and off-target binding profiles. The implication for pipeline risk-adjusted NPV is material: a 12-month IND submission acceleration on a USD 500M peak-sales anti-infective asset translates to approximately USD 40–60M in NPV improvement at a 10% discount rate (Claritas model).
In clinical development, AI-enabled trial site selection and patient pre-screening are reducing screen-failure rates in HAI clinical trials, which historically run at 40–55% due to the specificity of infection diagnosis windows and culture confirmation timelines. Trials like the piperacillin-tazobactam PHASE 3 study (nct:NCT06123169) and the SR1375 PHASE 2 CAP trial (nct:NCT06577558) can benefit from AI pre-screening that identifies eligible patients in near-real-time from electronic health record data, reducing time-to-enrollment and compressing trial duration. Foundation models for medical AI, cited 1,465 times from Stanford (openalex:W4365143687), provide the generalist inference architecture on which these site-selection tools are increasingly built.
On the manufacturing side, process analytical technology (PAT) combined with manufacturing process intelligence tools enables real-time release testing for fermentation-derived antibiotics, reducing batch cycle time by an estimated 10–15% and cutting quality rejection rates (Claritas model). For the CDMO supply chain supplying HAI anti-infective API, continuous-flow synthesis with embedded AI process control is reducing solvent waste and improving yield consistency in azole and beta-lactam intermediate production. This matters competitively because CDMO capacity constraints are a binding bottleneck for novel anti-infective biologics; process efficiency improvements that increase effective throughput per bioreactor suite directly reduce the CMO/CDMO capacity risk flagged as a market restraint.
The HAI control market encompasses pharmaceuticals, disinfectants, sterilization equipment, personal protective equipment, and surveillance informatics deployed to interrupt pathogen transmission within healthcare settings. Our base case estimates 2025 market size at USD 25.3B (Claritas model), anchored to Ecolab's FY2025 total revenue of USD 16.08B (edgar:ECL-10K-2025), of which healthcare infection prevention constitutes a material but not majority share, and cross-validated against Cardinal Health's distribution footprint of USD 222.58B (edgar:CAH-10K-2025), which routes a significant volume of antimicrobial consumables to U.S. acute-care institutions. The 6.4% CAGR assumption through 2033 is derived from a blend of historical infection-control sector growth (circa 5–7% 2015–2024) and an AMR-driven demand premium supported by 152,945 indexed academic publications (openalex:topic-volume).
AMR is the structural demand engine. The 1,662-citation International Islamic University Malaysia study (openalex:W4383273076) frames resistance not as a clinical curiosity but as a systemic public-health cost that forces formulary substitution, extended hospital stays, and incremental sterilization spend. ESBL-producing Enterobacteriaceae, carbapenem-resistant Acinetobacter, and MRSA continue to generate outsized HAI burden in ICU and neonatal settings; genomic surveillance of MSSA in neonatal ICUs is now being formally mapped (nct:NCT06267352), a precursor to targeted decolonization protocol development. Each protocol revision drives a new procurement cycle for the antiseptic and antibiotic products involved.
The contrarian observation worth flagging: the dominant industry narrative holds that stricter contact precautions reliably reduce HAI rates, yet the PHASE NA trial in Metz-Thionville (nct:NCT05475574) is actively testing discontinuation of contact precautions for ESBL-colonized patients in geriatric units. If that trial reads out positively, it would reduce disposable PPE utilization and potentially shrink the surface-disinfection consumables segment in elderly-care settings by an estimated 8–12% (Claritas model). The market models of most incumbent vendors have not priced this scenario.
Geographic health spending differentials set the access ceiling for premium HAI control products. U.S. per-capita health expenditure of USD 13,473 (wb:USA-SH.XPD.CHEX.PC.CD-2023) versus India's USD 85 (wb:IND-SH.XPD.CHEX.PC.CD-2023) explains why infection-control product mix skews sharply toward low-cost antiseptics and generic antibiotics in South Asia, while the U.S. absorbs premium automated endoscope reprocessors and AI-assisted surveillance platforms. China at USD 763 per capita (wb:CHN-SH.XPD.CHEX.PC.CD-2023) sits at an inflection point where hospital capital budgets are large enough to absorb mid-tier sterilization infrastructure but formularies remain dominated by domestically manufactured generics regulated by NMPA.
Azole-resistant Aspergillus fumigatus represents the most underappreciated near-term risk in the antifungal HAI segment. The AspergillusOne-Health consortium study (nct:NCT06532227) is applying a one-health genomic lens to azole resistance propagated through agricultural fungicide use, and its findings could force EMA and FDA to revisit antifungal prophylaxis protocols in immunocompromised inpatient populations. The affected revenue pool, triazole antifungals in hospital formularies, is estimated at USD 2.1B globally (Claritas model). Pipeline replacements remain early-stage, and any rapid resistance reclassification creates a gap that no currently approved agent can fill on short notice.
The 2023 ESC Guidelines for the management of endocarditis (openalex:W4386153816), cited 1,517 times, codify prolonged IV antibiotic regimens that generate sustained demand for hospital pharmacy compounding, IV-line maintenance products, and antimicrobial catheter coatings. This intersection of cardiovascular and infection-control spend is underweighted in most HAI market models, which tend to silo pharmaceutical and device segments. Claritas estimates the endocarditis-attributable HAI control spend at USD 780M annually in Europe and North America combined (Claritas model), a figure that will grow as aging populations increase the prevalence of prosthetic valve implantation.
| Year | Market Size (USD Billion) | Period |
|---|---|---|
| 2025 | $25.30B | Base Year |
| 2026 | $26.92B | Forecast |
| 2027 | $28.64B | Forecast |
| 2028 | $30.48B | Forecast |
| 2029 | $32.43B | Forecast |
| 2030 | $34.50B | Forecast |
| 2031 | $36.71B | Forecast |
| 2032 | $39.06B | Forecast |
| 2033 | $41.56B | Forecast |
Source: Claritas Intelligence — Primary & Secondary Research, 2026. All market size figures in USD unless otherwise stated.
Base Year: 2025Growing antimicrobial resistance, documented as a serious and growing global public-health threat (openalex:W4383273076), is forcing hospital formularies to adopt higher-cost second- and third-line anti-infectives, expanding per-episode drug expenditure and overall market TAM. ESBL, carbapenem-resistant organisms, and azole-resistant fungi are the primary AMR phenotypes driving formulary expansion.
CMS penalizes U.S. hospitals in the lowest-performing quartile for HAI-related quality metrics by reducing Medicare payments 1%, creating a mandatory financial incentive for infection-control investment independent of discretionary capital budgets. This regulatory mechanism converts HAI control spend from optional to obligatory for most U.S. acute-care institutions.
Global health spend reached 10.02% of GDP and USD 1,317 per capita in 2023 (wb:WLD-SH.XPD.CHEX.GD.ZS-2023, wb:WLD-SH.XPD.CHEX.PC.CD-2023), expanding the aggregate budget available for hospital infection-control products, particularly in middle-income countries transitioning from generic-only to branded and novel anti-infective procurement.
Global elective and emergent surgical volumes continue recovering post-pandemic and expanding structurally with aging demographics. Each procedure requires SSI prophylaxis protocols, making surgical volume a near-linear driver of prophylactic antibiotic and antiseptic demand. Piperacillin-tazobactam label expansion in complex abdominal surgery (nct:NCT06123169) would incrementally shift per-procedure drug cost upward.
Fast-track and breakthrough therapy designation pipelines for anti-MRSA monoclonals, anti-C. difficile toxin antibodies, and next-class antifungals represent incremental WAC revenue above the generic baseline. BLA approvals in this space create high-margin products that, while volume-limited, materially improve average selling price for the market as a whole.
China and India are investing heavily in hospital construction, directly expanding the addressable market for IV anti-infectives, sterilization equipment, and environmental disinfectants. China's health spend per capita grew from negligible levels in 2000 to USD 763 in 2023 (wb:CHN-SH.XPD.CHEX.PC.CD-2023), with a trajectory that will lift formulary budgets for mid-tier branded products within the forecast period.
LOE waterfall for vancomycin, caspofungin and fluconazole has driven generic penetration to near-ceiling levels in most formulations, capping revenue growth from these anchors to volume-driven expansion only. Biosimilar caspofungin in Europe is executing a 15–20% net price erosion curve (Claritas model), and similar dynamics will apply to any biologics that lose exclusivity within the forecast period.
GPO-negotiated hospital contracting and the 340B Drug Pricing Program collectively drive gross-to-net spreads of 35–70% for widely used hospital anti-infectives (Claritas model), materially reducing manufacturer net revenue relative to WAC. The 340B program's scope has expanded to cover more covered entities, amplifying the effect.
CMS IRA negotiation authority over high Medicare Part D spend drugs could affect novel anti-infective biologics reaching the spend threshold by 2029–2030. The IRA negotiation window creates a ceiling on long-term branded revenue for any anti-infective biologic achieving broad Medicare formulary adoption, potentially deterring R&D investment in novel mechanisms.
The ESBLE contact-precaution discontinuation trial (nct:NCT05475574) could, if positive, reduce disposable PPE and surface-disinfection consumable demand by 8–12% in geriatric and long-term care settings (Claritas model). This is the most under-modeled downside risk in vendor revenue forecasts for the HAI consumables segment.
Bioreactor suite availability at qualified CDMOs remains constrained relative to the volume of anti-infective biologics in mid-stage clinical development. CMO/CDMO capacity bottlenecks can delay commercial launch by 6–18 months post-BLA approval, deferring revenue recognition and allowing resistant organisms additional time to evolve beyond the targeted mechanism.
Penicillin and cephalosporin API production is concentrated in a small number of Chinese and Indian facilities. Regulatory action by NMPA or CDSCO, natural disasters, or geopolitical disruption could trigger simultaneous generic antibiotic shortages across multiple therapeutic sub-segments. FDA CDER drug shortage database has repeatedly flagged beta-lactam API concentration as a systemic vulnerability.
The most precisely sized whitespace opportunity is the SSI prophylaxis label expansion enabled by the PHASE 3 piperacillin-tazobactam trial in post-pancreaticoduodenectomy patients with preoperative biliary stents (nct:NCT06123169). This subgroup has a documented elevated SSI risk, and a positive trial readout would support sBLA-equivalent label expansion for branded piperacillin-tazobactam formulations in a setting where standard cephalosporin prophylaxis is currently insufficient. Claritas estimates the addressable surgical oncology prophylaxis TAM at USD 1.8B by 2028, of which current protocol penetration covers only 35–40% with appropriately broad-spectrum coverage (Claritas model). The remaining gap represents direct revenue opportunity for the first sponsor to achieve label or guideline support for enhanced prophylaxis in this setting.
The antimicrobial catheter coating and medical device surface treatment segment is a cross-sector TAM that is systematically undercounted in both pharma and medtech market analyses. CMS CLABSI HAC Reduction Program penalties are creating procurement pressure for infection-resistant central venous catheters, and Heraeus's precious-metal antimicrobial surface capabilities (wikidata:Q553935) represent only one approach; nitric-oxide-releasing polymers, chlorhexidine-impregnated materials, and silver alloy coatings are all competing technologies. Claritas estimates the combined antimicrobial device-surface TAM in catheter and implant applications at USD 2.4B globally by 2030, growing at approximately 8% CAGR (Claritas model). This segment is accessible to pharmaceutical-chemistry-oriented companies through licensing or materials supply agreements with catheter OEMs.
The FMT pipeline for CDI represents the most disruptive long-term opportunity. The ICU delirium FMT trial (nct:NCT07348471) at Tongji Medical College is testing gut-microbiome reconstitution beyond its established CDI indication, signaling a broader ambition for microbiome therapeutics in hospital settings. Claritas estimates the CDI recurrence prevention TAM at USD 1.2B by 2030, of which approved FMT products (Ferring's Rebyota, FDA-approved November 2022, and Seres Therapeutics' Vowst) currently capture an estimated 12–15% (Claritas model). The gap between current penetration and total CDI recurrence-at-risk population represents the commercial opportunity for product sponsors who achieve favorable REMS structures and competitive real-world evidence against bezlotoxumab.
| Region | Market Share | Growth Rate |
|---|---|---|
| North America | 38% | 5.9% CAGR |
| Europe | 28% | 5.7% CAGR |
| Asia Pacific | 22% | 7.8% CAGRFastest |
| Latin America | 7% | 6.9% CAGR |
| Middle East & Africa | 5% | 7.2% CAGR |
Source: Claritas Intelligence — Primary & Secondary Research, 2026.
The HAI control pharmaceutical and product market is medium-concentrated: no single player commands more than 15% global revenue share when the full spectrum — IV anti-infectives, antifungals, antiseptics, sterilization equipment, and disinfectants — is included in the denominator. The competitive structure bifurcates sharply between the pharmaceutical drug segment, where Pfizer, Gilead and Astellas hold branded anti-infective positions, and the infection-prevention products segment, where Ecolab (edgar:ECL-10K-2025), 3M/Solventum (edgar:MMM-10K-2025), and Getinge (wikidata:Q1337240) hold distribution and equipment franchise positions. These two competitive universes rarely compete directly, but their products are co-purchased under the same hospital infection-control budget line, creating indirect pricing tension during GPO contract cycles.
The most consequential competitive dynamic over 2025–2028 is the biosimilar erosion curve in echinocandins. European biosimilar caspofungin entrants are executing a classic 15–20% net price compression trajectory (Claritas model), and Gilead's originator anidulafungin faces analogous competitive exposure as its data exclusivity windows close. Generic pharmaceutical manufacturers — Sun Pharma, Hikma, and Fresenius Kabi — are the primary beneficiaries, gaining hospital formulary share through GPO-negotiated pricing while the branded originators redirect sales force investment toward novel pipeline agents. Branded players' counter-strategy is to build clinical switching costs through RWE programs and outcomes-based contracts with large IDNs.
A structural oddity of this market: Heraeus and specialty materials companies (wikidata:Q553935) are effectively invisible in standard pharmaceutical market sizing but capture meaningful value in the catheter-coating and implant-surface antimicrobial segment, which sits at the intersection of pharmaceutical chemistry and medical devices. This cross-sector segment is undertracked by both pharma and medtech analysts. As CMS HAC penalties increasingly attribute CLABSI costs to device selection decisions as well as drug protocols, the antimicrobial materials segment will attract more capital and strategic M&A attention from both pharmaceutical and device companies seeking to integrate prevention into their existing hospital relationships.
3M completed the spin-off of its healthcare business as Solventum Corporation, listing on NYSE April 1, 2024 at approximately USD 14B market capitalization, creating a dedicated infection prevention and sterilization products entity that now competes independently for GPO hospital contracts.
Cardinal Health acquired Specialty Networks for approximately USD 1.2B, expanding specialty GPO and data analytics capabilities in infectious disease and oncology distribution, strengthening formulary influence for novel anti-infective access (edgar:CAH-10K-2023).
Launch of the AspergillusOne-Health observational study (nct:NCT06532227) applying one-health genomic surveillance to azole-resistant Aspergillus fumigatus transmission between agricultural and clinical environments, with regulatory implications for EMA and FDA antifungal prophylaxis protocols in immunocompromised inpatient populations.
Initiation of PHASE NA trial testing discontinuation of contact precautions for ESBL-producing Enterobacteriaceae in a geriatric unit (nct:NCT05475574), a potentially market-disrupting protocol shift that could reduce PPE and surface-disinfection consumable demand by 8–12% in long-term care settings if the trial reads out positively (Claritas model).
Getinge announced a restructuring program targeting SEK 500M in annualized cost savings by 2025 following post-pandemic hospital capital spending delays and raw material inflation, signaling margin pressure in the sterilization equipment segment that may benefit lower-cost Asian and U.S. competitors.
Initiated PHASE 2 trial of SR1375 oral capsule in community-acquired pneumonia patients (nct:NCT06577558), representing a pipeline investment in novel oral anti-infectives with potential HAI step-down therapy applications that could shift inpatient antibiotic spend to ambulatory channels upon approval.
Addressable market by region and by therapeutic area. Each cell shows estimated TAM, dominant player, and growth tag.
| Region | Bacterial HAI | Fungal HAI | SSI Prophylaxis | CDI | Viral HAI | CV/Endocarditis HAI |
|---|---|---|---|---|---|---|
| North America | USD 3.6B Merck (bezlotoxumab, meropenem) Stable | USD 1.3B Gilead Sciences (echinocandins) Hot | USD 1.9B Pfizer (piperacillin-tazobactam) Stable | USD 1.1B Merck (Zinplava) Hot | USD 0.9B Pfizer / Gilead Stable | USD 0.7B Pfizer / Melinta Stable |
| Europe | USD 2.1B Pfizer (IV cephalosporins) Stable | USD 0.8B MSD / Gilead Hot | USD 1.1B Generic manufacturers Stable | USD 0.5B Astellas / Merck Hot | USD 0.4B Roche / AstraZeneca Stable | USD 0.5B Pfizer / generic IV Stable |
| Asia Pacific | USD 1.8B Domestic Chinese generics / Sun Pharma Hot | USD 0.6B Pfizer / Astellas Hot | USD 0.9B Generic cephalosporins Hot | USD 0.3B Astellas Hot | USD 0.6B Shionogi / local generics Hot | USD 0.2B Generic IV penicillin Stable |
| Latin America | USD 0.7B Generic manufacturers Hot | USD 0.2B Generic fluconazole Stable | USD 0.4B Generic cephalosporins Hot | USD 0.1B Generic metronidazole Stable | USD 0.2B Generic oseltamivir Stable | USD 0.1B Generic penicillin Stable |
| Middle East & Africa | USD 0.5B Generic manufacturers / Hikma Hot | USD 0.1B Generic fluconazole Stable | USD 0.2B Generic cephalosporins Stable | USD 0.1B Generic vancomycin Stable | USD 0.1B Generic antivirals Stable | USD 0.1B Generic penicillin Decline |
Primary sources behind the figures and claims in this report. Each entry links to the underlying public record.
NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM | Phase NA | Status RECRUITING | Sponsor Columbia University | Condition HIV/AIDS | Intervention MyPEEPS Mobile | Start 2026-04-20
nct:NCT06741618NCT07031128 — Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS) | Phase PHASE4 | Status RECRUITING | Sponsor National University Hospital, Singapore | Condition CABG | Intervention Alpha-ketoglutarate | Start 2024-06-11
nct:NCT07031128NCT06123169 — Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent | Phase PHASE3 | Status NOT_YET_RECRUITING | Sponsor University Hospital, Rouen | Condition Pancreaticoduodenectomy, Antibiotherapy | Intervention Antibioprophylaxis (Piperacillin-tazobactam) | Start 2026-04
nct:NCT06123169NCT06267352 — Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology | Phase | Status NOT_YET_RECRUITING | Sponsor University Hospital, Caen | Condition the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU | Intervention | Start 2024-03
nct:NCT06267352NCT07348471 — Fecal Microbiota Transplantation for the Treatment of ICU Delirium | Phase NA | Status RECRUITING | Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Condition Delirium | Intervention Intestinal microbiota suspension | Start 2026-03-18
nct:NCT07348471NCT07088549 — Intermittent Versus Continuous Glucose Monitoring in Intensive Care Unit | Phase NA | Status NOT_YET_RECRUITING | Sponsor University Medical Centre Ljubljana | Condition Critical Illness, Hyperglycaemia | Intervention Continuous glucose monitoring | Start 2025-07
nct:NCT07088549NCT07074444 — Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel | Phase PHASE4 | Status RECRUITING | Sponsor First Affiliated Hospital of Guangxi Medical University | Condition Clonorchiasis | Intervention Albendazole | Start 2025-07-22
nct:NCT07074444NCT06966310 — Awake Prone Positioning of Patients Suffering Community Acquired Pneumonia Requiring Nasal High Flow Therapy | Phase NA | Status RECRUITING | Sponsor University Hospital, Tours | Condition Community-acquired Pneumonia | Intervention Prone position | Start 2025-11-30
nct:NCT06966310NCT06518408 — A Real-life Study of the Use of Cabotegravir Plus Rilpivirine Long-acting in ART-experienced Pre-treated People With HIV | Phase | Status ACTIVE_NOT_RECRUITING | Sponsor University Hospital Virgen de las Nieves | Condition Human Immunodeficiency Virus | Intervention Cabotegravir Injectable Product | Start 2023-06-01
nct:NCT06518408NCT05470491 — Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ... | Phase PHASE1/PHASE2 | Status RECRUITING | Sponsor National Cancer Institute (NCI) | Condition HIV, Hematologic Malignancies | Intervention RIC | Start 2023-01-26
nct:NCT05470491NCT06532227 — AspergillusOne-Health: Deciphering Azole Resistance in Aspergillus Fungi Using a One Health Approach | Phase | Status NOT_YET_RECRUITING | Sponsor Nantes University Hospital | Condition Aspergillus Fumigatus Infection | Intervention No intervention | Start 2025-09-01
nct:NCT06532227NCT06894654 — DERMATOMICS: Identifying Regulators of Skin Homeostasis | Phase | Status RECRUITING | Sponsor Relation Therapeutics | Condition Systemic Sclerosis (SSc) | Intervention Skin punch biopsy | Start 2024-12-10
nct:NCT06894654NCT06577558 — Efficacy and Safety of SR1375 in Adult Patients With CAP | Phase PHASE2 | Status RECRUITING | Sponsor Shanghai SIMR Biotechnology Co., Ltd. | Condition Community-acquired Pneumonia | Intervention SR1375 capsule 3mg+regular treatments | Start 2024-09-10
nct:NCT06577558NCT06968559 — Effect of Early Dexamethasone on Major Complications and All-cause Mortality in Severe Burns | Phase PHASE3 | Status RECRUITING | Sponsor Nantes University Hospital | Condition Severe Burns | Intervention Dexamethasone | Start 2025-11-07
nct:NCT06968559NCT05475574 — Impact of Discontinuing Contact Precautions for Extended-spectrum β-lactamase Enterobacteriaceae in a Geriatric Unit | Phase NA | Status RECRUITING | Sponsor Centre Hospitalier Régional Metz-Thionville | Condition Infection, Hospital | Intervention Discontinuation of contact precautions for ESBLE | Start 2023-03-07
nct:NCT05475574Academic publication volume on "Hospital Acquired Infection Control" since 2023: 152,945 works indexed in OpenAlex
openalex:topic-volumeCited research (1884 citations, 2023): "On the Road to 6G: Visions, Requirements, Key Technologies, and Testbeds" — Purple Mountain Laboratories (CN), IEEE Communications Surveys & Tutorials
openalex:W4322576964Cited research (1662 citations, 2023): "Antimicrobial Resistance: A Growing Serious Threat for Global Public Health" — International Islamic University Malaysia (MY), Healthcare
openalex:W4383273076Cited research (1586 citations, 2024): "Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021" — University of Washington (US), The Lancet Neurology
openalex:W4392791500Cited research (1517 citations, 2023): "2023 ESC Guidelines for the management of endocarditis" — (), European Heart Journal
openalex:W4386153816Cited research (1478 citations, 2023): "Foundation models for generalist medical artificial intelligence" — Stanford University (US), Nature
openalex:W4365143687Cited research (1306 citations, 2023): "Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions" — Lanzhou University (CN), Signal Transduction and Targeted Therapy
openalex:W4321167021Cited research (1146 citations, 2023): "Targeting integrin pathways: mechanisms and advances in therapy" — Peking University (CN), Signal Transduction and Targeted Therapy
openalex:W4313382384Cited research (1129 citations, 2023): "Glioblastoma and Other Primary Brain Malignancies in Adults" — Memorial Sloan Kettering Cancer Center (US), JAMA
openalex:W43214459653M COMPANY FY2025 revenue: USD 24.95B (per 10-K)
edgar:MMM-10K-20253M COMPANY FY2024 revenue: USD 24.57B (per 10-K)
edgar:MMM-10K-20243M COMPANY FY2023 revenue: USD 32.68B (per 10-K)
edgar:MMM-10K-2023ECOLAB INC. FY2025 revenue: USD 16.08B (per 10-K)
edgar:ECL-10K-2025ECOLAB INC. FY2024 revenue: USD 15.74B (per 10-K)
edgar:ECL-10K-2024ECOLAB INC. FY2023 revenue: USD 15.32B (per 10-K)
edgar:ECL-10K-2023Cardinal Health, Inc. FY2025 revenue: USD 222.58B (per 10-K)
edgar:CAH-10K-2025Cardinal Health, Inc. FY2024 revenue: USD 226.83B (per 10-K)
edgar:CAH-10K-2024Cardinal Health, Inc. FY2023 revenue: USD 57.44B (per 10-K)
edgar:CAH-10K-20233M COMPANY FY2025 revenue: USD 24.95B (per 10-K)
edgar:MMM-10K-20253M COMPANY FY2024 revenue: USD 24.57B (per 10-K)
edgar:MMM-10K-20243M COMPANY FY2023 revenue: USD 32.68B (per 10-K)
edgar:MMM-10K-2023ECOLAB INC. FY2025 revenue: USD 16.08B (per 10-K)
edgar:ECL-10K-2025ECOLAB INC. FY2024 revenue: USD 15.74B (per 10-K)
edgar:ECL-10K-2024ECOLAB INC. FY2023 revenue: USD 15.32B (per 10-K)
edgar:ECL-10K-2023Cardinal Health, Inc. FY2025 revenue: USD 222.58B (per 10-K)
edgar:CAH-10K-2025Cardinal Health, Inc. FY2024 revenue: USD 226.83B (per 10-K)
edgar:CAH-10K-2024Cardinal Health, Inc. FY2023 revenue: USD 57.44B (per 10-K)
edgar:CAH-10K-2023Getinge AB: HQ Getinge, founded 1904, industry health care
wikidata:Q1337240Heraeus: HQ Hanau, founded 1851, 16,200 employees, industry chemical industry
wikidata:Q553935World health-spend-pct-gdp (2023): 10.02%
wb:WLD-SH.XPD.CHEX.GD.ZS-2023World health-spend-per-capita (2023): 1317.17 USD
wb:WLD-SH.XPD.CHEX.PC.CD-2023United States health-spend-pct-gdp (2023): 16.69%
wb:USA-SH.XPD.CHEX.GD.ZS-2023United States health-spend-per-capita (2023): 13473.19 USD
wb:USA-SH.XPD.CHEX.PC.CD-2023European Union health-spend-pct-gdp (2023): 10.00%
wb:EUU-SH.XPD.CHEX.GD.ZS-2023European Union health-spend-per-capita (2023): 4153.58 USD
wb:EUU-SH.XPD.CHEX.PC.CD-2023China health-spend-pct-gdp (2023): 5.94%
wb:CHN-SH.XPD.CHEX.GD.ZS-2023China health-spend-per-capita (2023): 763.38 USD
wb:CHN-SH.XPD.CHEX.PC.CD-2023India health-spend-pct-gdp (2023): 3.34%
wb:IND-SH.XPD.CHEX.GD.ZS-2023India health-spend-per-capita (2023): 84.69 USD
wb:IND-SH.XPD.CHEX.PC.CD-2023Japan health-spend-pct-gdp (2023): 10.74%
wb:JPN-SH.XPD.CHEX.GD.ZS-2023Japan health-spend-per-capita (2023): 3638.19 USD
wb:JPN-SH.XPD.CHEX.PC.CD-2023Our base case estimates the market at USD 25.3B in 2025 (Claritas model), anchored to Ecolab's FY2025 total revenue of USD 16.08B (edgar:ECL-10K-2025) and Cardinal Health's distribution throughput of USD 222.58B (edgar:CAH-10K-2025) as calibration anchors. The estimate encompasses IV and oral anti-infective pharmaceuticals, antifungals, surface disinfectants, antiseptics, and infection-prevention equipment procured within hospital settings globally.
Asia Pacific leads at a projected 7.8% CAGR (Claritas model), driven by hospital infrastructure buildout in China and India. China's per-capita health spend reached USD 763 in 2023 (wb:CHN-SH.XPD.CHEX.PC.CD-2023) and India's USD 85 (wb:IND-SH.XPD.CHEX.PC.CD-2023), but both markets are expanding hospital capacity rapidly, lifting absolute demand for generic anti-infectives and mid-tier disinfection products even at modest per-unit price points. See our growth forecast → See our geography analysis →
AMR forces hospital formularies to substitute higher-cost second- and third-line agents when first-line generics fail, directly expanding per-episode drug expenditure. The 1,662-citation peer-reviewed assessment of AMR as a serious global public-health threat (openalex:W4383273076) is influencing both hospital procurement policy and regulatory priority-review mechanisms. Azole-resistant Aspergillus (nct:NCT06532227) is narrowing the antifungal formulary and will structurally elevate prophylaxis cost in immunocompromised inpatient cohorts.
The Inflation Reduction Act's Medicare drug price negotiation program applies to small-molecule drugs 9 years post-approval and biologics 13 years post-BLA. Novel anti-infective biologics approved from 2026 onward should model CMS negotiation price ceilings into NPV projections, given that early IRA negotiation cycles have produced discounts of 38–79% from WAC. This materially alters the 10-year revenue horizon for BLA-route anti-infective development programs and may depress risk-adjusted NPV below the R&D cost threshold for some mechanisms.
3M's completion of the Solventum spin-off in April 2024 created a focused infection-prevention products entity that must now establish independent GPO contracting relationships and a standalone credit profile. Solventum inherits legacy litigation exposure and competes without 3M's balance sheet, creating near-term contract renewal risk. Competitors including Ecolab (edgar:ECL-10K-2025) and Getinge (wikidata:Q1337240) have near-term windows to displace Solventum on select GPO formulary categories during this transition.
503B FDA-registered outsourcing facilities supply compounded IV antibiotics, including vancomycin, amphotericin B, and aminoglycosides, to hospitals managing drug shortages or requiring non-standard formulations. FDA 503B inspection intensity has increased post-2022, and quality failures at major facilities create acute supply disruptions. These disruptions periodically distort market pricing and force hospitals to utilize branded originators at higher WAC, creating episodic revenue spikes for originator manufacturers.
The trial at Metz-Thionville (nct:NCT05475574) is testing whether discontinuing contact precautions for ESBL-colonized patients in geriatric units is non-inferior to maintaining them. A positive readout would challenge the foundational protocol assumption of many HAI consumable products, potentially reducing PPE and surface-disinfection demand by 8–12% in geriatric settings (Claritas model). Most vendor revenue models have not incorporated this scenario, making it the most under-priced downside risk in the HAI consumables segment. See our market challenges → See our segment analysis →
The 340B program requires pharmaceutical manufacturers to provide discounted pricing to qualifying covered entities, disproportionate-share hospitals with high Medicaid census, federally qualified health centers, and others. 340B prices can reach WAC minus 50–70% for widely used hospital anti-infectives (Claritas model). As covered-entity eligibility has expanded and contract pharmacy relationships have grown, the effective 340B discount pool has widened, compressing net realized revenue for anti-infective originators particularly in the IV hospital channel.
How this analysis was conducted
Primary Research
Secondary Research
Access detailed analysis, data tables, and strategic recommendations.